Albireo Pharma (ALBO) Reports FY16 Loss of $13.16

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. HNGE
8. INSP
9. MRVL
10. MTCH

Go back to Albireo Pharma (ALBO) Reports FY16 Loss of $13.16

Albireo Reports 2016 Financial Results

March 14, 2017 7:30 AM EDT

Promising Phase 2 data for A4250 in pediatric cholestatic liver disease

Initiation of A4250 Phase 3 trial planned for 2H 2017

JNDA filing for elobixibat by licensee EA Pharma

Consummation of business combination to become NASDAQ listed

Conference call today at 8:30 a.m. ET

BOSTON, March 14, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO), an orphan pediatric liver disease company developing novel bile acid modulators, today... More